Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review.

abstract：:This report describes two cases of T-cell chronic lymphocytic leukemia (T-CLL) treated with purine nucleoside analogues. One patient had CD8+, CD3+ large granular lymphocytosis (LGL) producing transfusion-dependent anemia and was refractory to chemotherapy. Treatment with four cycles of fludarabine produced a clinical...

journal_title：Leukemia & lymphoma

authors： Witzig TE,Weitz JJ,Lundberg JH,Tefferi A

更新日期：1994-06-01 00:00:00

abstract：:Since unlimited proliferative potential has been identified as a major and, to date, therapeutically unexploited phenotypic hallmark of cancer, telomere maintenance mechanisms have been proposed as potential targets for new anticancer interventions. This study was aimed to investigate the effects of BIBR1532, the lead...

journal_title：Leukemia & lymphoma

authors： Bashash D,Ghaffari SH,Mirzaee R,Alimoghaddam K,Ghavamzadeh A

更新日期：2013-03-01 00:00:00

abstract：:We investigated the possibility of immunotherapy for multiple myeloma (MM) using myeloma-specific cytotoxic T lymphocytes (CTLs) that were stimulated in vitro by dendritic cells (DCs) pulsing with purified and optimized myeloma lysates. CD14(+) cells were cultured in the presence of GM-CSF and IL-4. On day 6, the imma...

journal_title：Leukemia & lymphoma

authors： Lee JJ,Choi BH,Kang HK,Park MS,Park JS,Kim SK,Pham TN,Cho D,Nam JH,Kim YJ,Rhee JH,Yang DH,Kim YK,Kim HJ,Chung IJ

更新日期：2007-10-01 00:00:00

abstract：:The Rai and Binet staging systems, which are used as standard methods for evaluating the prognosis of chronic lymphocytic leukemia (CLL), have some restrictions in identifying patients with early-stage CLL who will progress rapidly. To solve this defect, other prognostic parameters have become important in recent year...

journal_title：Leukemia & lymphoma

authors： Hancer VS,Kose M,Diz-Kucukkaya R,Yavuz AS,Aktan M

更新日期：2011-01-01 00:00:00

abstract：:A review of recent information on the expression and the ATRA-driven modulation of cell surface adhesion molecules of acute myelogenous leukemia blast cells is presented. Cytofluorometric studies on fresh blast cells have demonstrated that CD11a, CD11b CD11c, CD15, CD45RO and CD54 expression is significantly lower in ...

journal_title：Leukemia & lymphoma

authors： Di Noto R,Lo Pardo C,Schiavone EM,Ferrara F,Manzo C,Vacca C,Del Vecchio L

更新日期：1996-04-01 00:00:00

abstract：:We present a rare case of central nervous system lymphoma that occurred in a patient who had essential thrombocythemia for 17 years. MRI examinations disclosed multiple ring-enhanced lesions that had shown bilateral spreading in the different period. Pathological examinations confirmed CD30/Ki-1-positive ALK negative ...

journal_title：Leukemia & lymphoma

authors： Tajima Y,Miyazaki Y,Higashi T,Kishimoto R,Sudoh K,Matsumoto A,Kikuchi S,Tashiro K

更新日期：2003-07-01 00:00:00

abstract：:A 55-year-old Jewish patient was simultaneously diagnosed as having Gaucher's disease and IgA multiple myeloma. Serum protein electrophoresis and immunoelectrophoresis showed two different IgA kappa type monoclonal spikes. After four years of observation, a rapid fatal course of disease developed together with express...

journal_title：Leukemia & lymphoma

authors： Shvidel L,Hurwitz N,Shtalrid M,Zur S,Oliver O,Berrebi A

更新日期：1995-12-01 00:00:00

abstract：:The ubiquitin-proteasome-dependent proteolytic system has been reported to regulate apoptotic cell death in many experimental cell models. We recently found that B-CLL (chronic lymphocytic leukemia) lymphocytes are hypersensitive to apoptotic death activation through specific inhibition of proteasome function by lacta...

journal_title：Leukemia & lymphoma

authors： Masdehors P,Merle-Béral H,Magdelénat H,Delic J

更新日期：2000-08-01 00:00:00

abstract：:The objective of this work was to determine the safety and efficacy of gemtuzumab ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the following diagnoses/characteristics were treated with 1-3 infusions of gemtuzumab ozogamicin at a dose of 9 mg/m2: (1) relapse of AML < or = 6 mon...

journal_title：Leukemia & lymphoma

authors： Roboz GJ,Knovich MA,Bayer RL,Schuster MW,Seiter K,Powell BL,Woodruff RD,Silver RT,Frankel AE,Feldman EJ

更新日期：2002-10-01 00:00:00

abstract：:Multiple genes have been identified to cause hereditary predispositions to hematologic malignancies, and characterized by an increased risk to develop myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and/or aplastic anemia (AA). Referral algorithms for patients who may be at higher risk have been propose...

journal_title：Leukemia & lymphoma

authors： Clifford M,Bannon S,Bednar EM,Czerwinski J,Davis J,Dunnington L,Shahrukh Hashmi S,DiNardo CD

更新日期：2019-12-01 00:00:00

abstract：:We have identified a family in which three members developed B-cell lymphoproliferative disorders within a nine month period. The 33 year old proband and his mother have hairy cell leukemia, and his 37 year old brother developed a large cell lymphoma. Chromosomal fragile site analysis of peripheral blood lymphocytes o...

journal_title：Leukemia & lymphoma

authors： Moormeier JA,Neilly ME,Vardiman JW,Le Beau MM,Golomb HM

更新日期：1991-01-01 00:00:00

abstract：:The cytokine IL-6 has been proposed as an autocrine growth factor in multiple myeloma, and is also required for stimulation of immunoglobulin production and secretion in normal plasma cells and myeloma cells. In this study, we showed that secreted IL-6 is detectable by Western blot analysis in a panel of lymphoid and ...

journal_title：Leukemia & lymphoma

authors： Shiao RT,McLeskey SB,Khera SY,Wolfson A,Freter CE

更新日期：1996-04-01 00:00:00

abstract：:This case is of an unusual florid reactive CD4+ T Cell lymphocytosis involving lymph node (LN) and overshadowing residual B chronic lymphocytic leukemia (CLL). A 65 year old female with a 9 year history of untreated B-CLL presented with weight loss, splenomegaly and lymphadenopathy. B-CLL was confirmed on the basis of...

journal_title：Leukemia & lymphoma

authors： Busmanis I,Hussein S,Feleppa F,Rockman S,Begley CG

更新日期：1993-01-01 00:00:00

abstract：:Older patients with acute myeloid leukemia (AML) frequently have significant comorbidities, geriatric syndromes, and high-risk leukemia that make them susceptible to high early mortality, chemotherapy-related toxicities, and poor long-term survival. The receipt of chemotherapy or hematopoietic cell transplantation is ...

journal_title：Leukemia & lymphoma

authors： Bhatt VR,Gundabolu K,Koll T,Maness LJ

更新日期：2018-01-01 00:00:00

abstract：:The approval of venetoclax, a 'BH3-mimetic' antagonist of the BCL-2 anti-apoptotic protein, for chronic lymphocytic leukemia represents a major milestone in translational apoptosis research. Venetoclax has already received 'breakthrough' designation for acute myeloid leukemia, and is being studied in many other tumor ...

journal_title：Leukemia & lymphoma

authors： Bose P,Gandhi V,Konopleva M

更新日期：2017-09-01 00:00:00

abstract：:Multiple myeloma (MM) is the top indication for high-dose chemotherapy (HDC) with autologous stem cell transplantation (SCT), a strategy which improves progression-free survival and potentially overall survival (OS). Novel induction regimens incorporating the immunomodulatory (IMID) agents, such as thalidomide and len...

journal_title：Leukemia & lymphoma

authors： Benson DM Jr,Panzner K,Hamadani M,Hofmeister CC,Bakan CE,Smith MK,Elder P,Krugh D,O'Donnell L,Devine SM

更新日期：2010-02-01 00:00:00

abstract：:Granulocytic sarcomas (GS) are rare extra medullary tumors composed of myeloid progenitor cells. Bones, lymph nodes and skin are favored sites of involvement. Primary involvement of the ovary is exceedingly rare leading to under diagnosis of GS. We report on a 19-year-old woman who presented with an ovarian mass witho...

journal_title：Leukemia & lymphoma

authors： Mehta J,Kane S

更新日期：2004-04-01 00:00:00

abstract：:Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphomas (NHL) characterized in almost all cases by the chromosomal translocation t(11;14)(q13;q32) and nuclear cyclin D1 overexpression. Most patients present with advanced stage disease, often with extranodal dissemination, and typically pursue an...

journal_title：Leukemia & lymphoma

authors： Weigert O,Unterhalt M,Hiddemann W,Dreyling M

更新日期：2009-12-01 00:00:00

abstract：:Myeloproliferative neoplasms (MPNs) are associated with pulmonary hypertension (PH). We studied MPN patients who underwent right-heart-catheterization (RHC) to identify hemodynamic differences between MPN-subtypes. Per RHC, hemodynamics were classified as pre, post or combined pre and post-capillary PH. One-way analys...

journal_title：Leukemia & lymphoma

authors： Khan NA,Ahuja KA,Wang X,Chaisson NF

更新日期：2021-01-25 00:00:00

abstract：:The purpose of this study was to better define the clinical features and natural history of peripheral T-cell lymphomas (PTCL) entities included in the Revised European American lymphoma (REAL) classification. Cases of PTCL were retrieved from the records of the Department of Pathology and classified according to the ...

journal_title：Leukemia & lymphoma

authors： Arrowsmith ER,Macon WR,Kinney MC,Stein RS,Goodman SA,Morgan DS,Flexner JM,Cousar JB,Jagasia MH,McCurley TL,Greer JP

更新日期：2003-02-01 00:00:00

abstract：:Bone marrow scintigraphy is a simple and noninvasive examination useful to define the status of the bone marrow and spleen in polycythaemia vera (P.V.). Despite the absence of specificity of Indium 111 labelled transferrin (In-Tf) for myelopoietic tissue, there is a close correlation between bone marrow In-Tf uptake a...

journal_title：Leukemia & lymphoma

authors： Rain JD,Najean Y,Billotey C

更新日期：1996-09-01 00:00:00

abstract：:The prognostic value of positron emission tomography (PET) in early therapy response assessment, after completion of chemotherapy and 3 months after the end of treatment in advanced Hodgkin lymphoma (HL) remains to be defined. We report the results of 69 patients with first presentation of advanced HL. [18F]-fluoro-2-...

journal_title：Leukemia & lymphoma

authors： Markova J,Kahraman D,Kobe C,Skopalova M,Mocikova H,Klaskova K,Dedeckova K,Eich HT,Böll B,Dietlein M,Kozak T

更新日期：2012-01-01 00:00:00

abstract：:A phase I/II clinical study evaluated 17 patients with refractory/recurrent acute leukemia treated with 1.5 mg/m2/day topotecan on days 1-3 followed by etoposide (100 mg/m2/day)+mitoxantrone (10 mg/m2/day) on days 4, 5 and 9, 10. Timed sequential chemotherapy using the topoisomerase I-inhibitor topotecan before the to...

journal_title：Leukemia & lymphoma

authors： Mainwaring MG,Rimsza LM,Chen SF,Gomez SP,Weeks FW,Reddy V,Lynch J,May WS,Kahn S,Moreb J,Leather H,Braylan R,Rowe TC,Fieniewicz KJ,Wingard JR

更新日期：2002-05-01 00:00:00

abstract：:We describe a patient with extranodal (pulmonary) marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) who was refractory to treatment with cytotoxic chemotherapy. After a single four-week course of rituximab she had significant regression of pulmonary lesions and remains progression free 19 month...

journal_title：Leukemia & lymphoma

authors： Chong EA,Svoboda J,Cherian S,Andreadis C,Downs LH,Zhuang H,Alavi A,Tsai DE,Schuster SJ

更新日期：2005-09-01 00:00:00

abstract：:This open-label, phase 1 study evaluated the effects of ofatumumab on QTc intervals, safety, efficacy, B-cell and neutrophil counts, complement levels, and cytokine and chemokine concentrations. Fourteen patients with fludarabine-refractory chronic lymphocytic leukemia received 12 ofatumumab infusions. A higher maximu...

journal_title：Leukemia & lymphoma

authors： Patton WN,Lindeman R,Butler AC,Kipps TJ,Jewell RC,Laubscher KH,Zhou YY,Lewis E,Sedoti D,Witman P,Fang L,Chan G

更新日期：2015-01-01 00:00:00

abstract：:Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma. Main toxicity usually consists in somnolence, constipation, peripheral neuropathy and deep vein thrombosis, but, unlike alkylating agents, thalidomide is reported to rarely induce severe hematologic toxicity. The majority of patie...

journal_title：Leukemia & lymphoma

authors： Mazzotta S,Gozzetti A,Pirrotta MT,Bocchia M,Sammassimo S,Bucalossi A,Lauria F

更新日期：2005-12-01 00:00:00

abstract：:Central to discovering novel approaches to treating leukemias and lymphomas is a clear understanding of the signaling networks which lead to unchecked cell cycle progression, proliferation, and survival. Cyclic-adenosine monophosphate (cAMP) responsive element-binding protein (CREB) represents a critical integrator of...

journal_title：Leukemia & lymphoma

authors： Mitton B,Cho EC,Aldana-Masangkay GI,Sakamoto KM

更新日期：2011-11-01 00:00:00

abstract：:Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disrupting cell-cell interac...

journal_title：Leukemia & lymphoma

authors： Pleyer C,Wiestner A,Sun C

更新日期：2018-12-01 00:00:00

abstract：:Plasma cell tumors show an increased incidence in HIV-positive patients. The cases reported in the literature suggest that plasma cell tumors occur in a younger age group than that encountered in the general population. Pathologically, many of these tumors show a plasmablastic morphology. Plasma cell tumors in HIV-pos...

journal_title：Leukemia & lymphoma

authors： Salarieh A,Rao C,Gottesman SR,Alagha O,Todor R,Axiotis CA

更新日期：2005-07-01 00:00:00

abstract：:Abstract Increasing manganese superoxide dismutase (MnSOD) expression can suppress the malignant phenotype in various cancer cell lines and suppress tumor formation in xenograft and transgenic mouse models. A mimic of manganese superoxide dismutase (MnSODm), synthesized by a chemical method, has been shown to possess ...

journal_title：Leukemia & lymphoma

authors： Wang YH,Xu XJ,Zhang LF,Li HL

更新日期：2014-05-01 00:00:00